Literature DB >> 15498047

Increased CCR4 expression on circulating CD4(+) T cells in ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus.

P T Yang1, H Kasai, L J Zhao, W G Xiao, F Tanabe, M Ito.   

Abstract

Previous studies have suggested that CCR4 is particularly important in the selective recruitment of various subsets of leucocytes in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In this study, we examined the percentage of CD4(+)/CCR4(+) T cells within circulating lymphocytes in active ankylosing spondylitis (AS), RA and SLE patients. The clinical significance of CCR4 expression as well as possible associations between the expression and serum levels of tumour necrosis factor (TNF)-alpha, interferon (IFN)-gamma and interleukin (IL)-10 were also examined. Our results showed that the percentage of CD4(+)/CCR4(+) T cells was significantly elevated in AS and RA patients as compared with normal controls. The percentage was also significantly higher in SLE patients who had received no treatment with glucocorticoids or cytotoxic drugs (untreated SLE) than that in controls. In addition, the percentage of CD4(+)/CCR4(+) T cells showed significant positive correlations with the Bath ankylosing spondylitis disease activity index (BASDAI) in AS and with the SLE disease activity index (SLEDAI) in untreated SLE. Of all the cytokines examined, the elevated serum IL-10 level was closely correlated with the percentage of CD4(+)/CCR4(+) T cells in AS, RA and untreated SLE. These results suggest that CCR4 may be crucial in the pathogenesis of AS, RA and SLE. The percentage of CD4(+)/CCR4(+) T cells can serve as a useful marker for the activity of AS and untreated SLE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15498047      PMCID: PMC1809206          DOI: 10.1111/j.1365-2249.2004.02617.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis.

Authors:  K J Katschke; J B Rottman; J H Ruth; S Qin; L Wu; G LaRosa; P Ponath; C C Park; R M Pope; A E Koch
Journal:  Arthritis Rheum       Date:  2001-05

2.  Therapeutic criteria in rheumatoid arthritis.

Authors:  O STEINBROCKER; C H TRAEGER; R C BATTERMAN
Journal:  J Am Med Assoc       Date:  1949-06-25

3.  New York clinical criteria for ankylosing spondylitis. A statistical evaluation.

Authors:  J M Moll; V Wright
Journal:  Ann Rheum Dis       Date:  1973-07       Impact factor: 19.103

4.  Increased CCR4 expression in active systemic lupus erythematosus.

Authors:  K Hase; K Tani; T Shimizu; Y Ohmoto; K Matsushima; S Sone
Journal:  J Leukoc Biol       Date:  2001-11       Impact factor: 4.962

5.  Selective accumulation of CCR4+ T lymphocytes into renal tissue of patients with lupus nephritis.

Authors:  Masato Yamada; Hideo Yagita; Hideko Inoue; Tsuyoshi Takanashi; Hironori Matsuda; Eiko Munechika; Yutaka Kanamaru; Isao Shirato; Yasuhiko Tomino; Kouji Matushima; Ko Okumura; Hiroshi Hashimoto
Journal:  Arthritis Rheum       Date:  2002-03

6.  Selective lymphocyte chemokine receptor expression in the rheumatoid joint.

Authors:  J H Ruth; J B Rottman; K J Katschke; S Qin; L Wu; G LaRosa; P Ponath; R M Pope; A E Koch
Journal:  Arthritis Rheum       Date:  2001-12

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  A role for TARC/CCL17, a CC chemokine, in systemic lupus erythematosus.

Authors:  Hiroshi Okamoto; Kyoko Koizumi; Hisashi Yamanaka; Terunobu Saito; Naoyuki Kamatani
Journal:  J Rheumatol       Date:  2003-11       Impact factor: 4.666

Review 9.  Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease.

Authors:  Parris Kidd
Journal:  Altern Med Rev       Date:  2003-08

10.  Efficacy of low-dose methotrexate in rheumatoid arthritis.

Authors:  M E Weinblatt; J S Coblyn; D A Fox; P A Fraser; D E Holdsworth; D N Glass; D E Trentham
Journal:  N Engl J Med       Date:  1985-03-28       Impact factor: 91.245

View more
  25 in total

1.  Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis.

Authors:  C Duftner; C Dejaco; W Kullich; A Klauser; C Goldberger; A Falkenbach; M Schirmer
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

2.  Pregnancy outcomes in women with rheumatoid arthritis in Washington State.

Authors:  Susan D Reed; Teresa A Vollan; Megan A Svec
Journal:  Matern Child Health J       Date:  2006-07

3.  Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5+ and CXCR3+ CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA).

Authors:  A Aggarwal; S Agarwal; R Misra
Journal:  Clin Exp Immunol       Date:  2007-03-21       Impact factor: 4.330

4.  Distinct effects of anti-tumor necrosis factor combined therapy on TH1/TH2 balance in rheumatoid arthritis patients.

Authors:  S Herman; N Zurgil; S Machlav; A Shinberg; P Langevitz; M Ehrenfeld; M Deutsch
Journal:  Clin Vaccine Immunol       Date:  2011-05-18

Review 5.  FcgammaRII and multi-system autoimmune disease.

Authors:  Nicholas C van de Velde; Patricia L Mottram; P Mark Hogarth
Journal:  Springer Semin Immunopathol       Date:  2006-11-08

Review 6.  Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus.

Authors:  Hui Peng; Wei Wang; Mo Zhou; Rui Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2013-05-25       Impact factor: 2.980

7.  Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis.

Authors:  N-S Lai; H-C Yu; H-C Chen; C-L Yu; H-B Huang; M-C Lu
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

8.  The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study.

Authors:  Balázs Szalay; Barna Vásárhelyi; Aron Cseh; Tivadar Tulassay; Magdolna Deák; László Kovács; Attila Balog
Journal:  Clin Rheumatol       Date:  2013-08-11       Impact factor: 2.980

9.  Distinct expression of chemokine-like factor 1 in synovium of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

Authors:  Ke Tao; Xu Tang; Bin Wang; Ru-Jun Li; Bao-Qing Zhang; Jian-Hao Lin; Hu Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-02-03

10.  Adaptive immunity in ankylosing spondylitis: phenotype and functional alterations of T-cells before and during infliximab therapy.

Authors:  Balázs Szalay; Gergo Mészáros; Áron Cseh; Lilla Ács; Magdolna Deák; László Kovács; Barna Vásárhelyi; Attila Balog
Journal:  Clin Dev Immunol       Date:  2011-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.